Bi-ligand drug conjugate and use thereof
AssigneeCoherent Biopharma (Suzhou), Limited
InventorsBaohua Robert HUANG, Wei TAN, Jian DAI, Zhongbo WANG, Xiaodong LIU, Xinli HU, Xueyuan XIE, Jun SHAO
Life of this patent
Estimating the term…
Loading patent…
AssigneeCoherent Biopharma (Suzhou), Limited
InventorsBaohua Robert HUANG, Wei TAN, Jian DAI, Zhongbo WANG, Xiaodong LIU, Xinli HU, Xueyuan XIE, Jun SHAO
Estimating the term…
The present disclosure discloses a conjugate compound or a pharmaceutically acceptable salt thereof, comprising a payload and two targeting molecules. Further disclosed herein is a pharmaceutical composition, comprising the conjugate compound or the pharmaceutically acceptable salt thereof. The present disclosure additionally relates to a method for delivering a payload to a subject in need thereof, and a method for treating a disease, wherein the methods comprise administering to the subject a therapeutically effective amount of the conjugate compound or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition as disclosed herein.
A conjugate compound or a pharmaceutically acceptable salt thereof, comprising a payload and two targeting molecules, wherein the two targeting molecules are a synergistic molecule moiety and a prostate-specific membrane antigen ligand moiety, respectively.
6-11. (canceled)
(canceled)
(canceled)
18-19. (canceled)
The conjugate compound or the pharmaceutically acceptable salt thereof according to claim 19, wherein the payload is a small molecule compound.
(canceled)
25-28. (canceled)
33-34. (canceled)
36-37. (canceled)
40-46. (canceled)
Dependencies are inferred from the claim text.